Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst

Angelini Pharma completed its $4.1 billion acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals, structured with Italian state lender CDP. The close of this large deal is a meaningful expansion of Angelini’s rare-disease portfolio and can be expected to shift investor focus toward growth and integration execution post-merger.

Analysis

Angelini Pharma completed its $4.1 billion acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals, structured with Italian state lender CDP. The close of this large deal is a meaningful expansion of Angelini’s rare-disease portfolio and can be expected to shift investor focus toward growth and integration execution post-merger.